Announcing a New Era in Alzheimer's The Time for Tau is NowIn an area where an effective disease-modifying therapy greatly needed, Professor Wischik is on the verge of becoming an overnight success — 30-plus years in the making — if the Phase III trials for LMTX®, the second-generation tau aggregation inhibitor (TAI), prove to be as successful as the Phase II trials of its predecessor, rember®. Data released in 2008 from Phase II trials involving 321 patients with mild and moderate Alzheimer’s disease revealed a 80% - 90% reduction in the rate of disease progression over two years in mild-moderate Alzheimer’s patients. While the results drew media attention at the time, they barely made a ripple in the Alzheimer’s community. However, recent clinical failures with products addressing the beta amyloid pathway now have some believing that a tau-based product is industry’s next best hope for a successful Alzheimer’s treatment. The implications are vast – this could be one of the biggest discoveries in modern history.
Prof. Wischik remains committed to pursuing the tau tangles and is confident that LMTX® is the right way forward. If he is right, TauRx Therapeutics, as well as the Alzheimer’s patient and caregiver community, will be the big winners.
At the same time, Prof. Wischik is quick to point out that in the end it’s not about the money; it’s about doing the right thing. And that right thing is bringing to patients a treatment that halts or reverses the devastating affects of Alzheimer’s.
Event: Live Press Conference / Webinar in Conjunction with the 5th Clinical Trials Conference on Alzheimer's Disease
Date: Tuesday, 30th Octoer 2012
Time: 16:00 - 16:45 Monte Carlo (Central European Time); 15:00 - 15:45 London (GMT); 11:00 - 11:45 New York City (EST); 8:00 - 8:45 Los Angeles (PST)
Where: Grimaldi Forum, Monte Carlo
Please provide you details in order to register for this webinar. Afterwards we will send you an email confirming your registration.
Please complete the form below and click the 'submit' button to register.